Assembly Biosciences, Inc. (ASMB)
Largest Insider Buys in Sector
ASMB Stock Price History Chart
ASMB Stock Performance
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and …
Insider Activity of Assembly Biosciences, Inc.
Over the last 12 months, insiders at Assembly Biosciences, Inc. have bought $21.24M and sold $139,156 worth of Assembly Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Assembly Biosciences, Inc. have bought $10.76M and sold $159,949 worth of stock each year.
Highest buying activity among insiders over the last 12 months: GILEAD SCIENCES, INC. (10 percent owner) — $100.49M. Schornstein Alexander (10 percent owner) — $1.14M.
The last purchase of 940,499 shares for transaction amount of $20.1M was made by GILEAD SCIENCES, INC. (10 percent owner) on 2024‑12‑19.
List of Insider Buy and Sell Transactions, Assembly Biosciences, Inc.
| 2024-12-19 | 10 percent owner | 940,499 20.3736% | $21.37 | $20.1M | -0.95% | |||
| 2024-11-25 | 10 percent owner | 7,976 0.126% | $14.91 | $118,890 | +8.37% | |||
| 2024-11-22 | 10 percent owner | 17,024 0.2729% | $14.87 | $253,104 | +5.02% | |||
| 2024-11-18 | Sale | Chief Manufacturing Officer | 40 0.0006% | $16.29 | $652 | -1.96% | ||
| 2024-10-08 | 10 percent owner | 10,000 0.1478% | $14.58 | $145,800 | +14.36% | |||
| 2024-10-03 | Sale | CEO and President | 197 0.003% | $14.81 | $2,918 | +11.64% | ||
| 2024-10-03 | Sale | Chief Manufacturing Officer | 157 0.0024% | $14.81 | $2,325 | +11.64% | ||
| 2024-08-02 | Sale | CEO and President | 981 0.0158% | $14.23 | $13,962 | +13.79% | ||
| 2024-08-02 | Sale | Chief Manufacturing Officer | 785 0.0127% | $14.23 | $11,173 | +13.79% | ||
| 2024-07-05 | 10 percent owner | 4,438 0.063% | $12.52 | $55,564 | 0.00% | |||
| 2024-07-03 | 10 percent owner | 4,562 0.0636% | $12.29 | $56,067 | 0.00% | |||
| 2024-06-17 | 10 percent owner | 179,500 0.0002% | $0.00 | $180 | +4.49% | |||
| 2024-05-23 | Sale | director | 2,117 0.0389% | $14.93 | $31,615 | +4.44% | ||
| 2024-05-23 | Sale | CEO and President | 549 0.0101% | $14.93 | $8,199 | +4.44% | ||
| 2024-05-23 | Sale | Chief Manufacturing Officer | 172 0.0032% | $14.93 | $2,569 | +4.44% | ||
| 2024-05-23 | Sale | Principal Accounting Officer | 24 0.0004% | $14.93 | $358 | +4.44% | ||
| 2024-04-30 | Sale | CEO and President | 1,569 0.0292% | $12.71 | $19,937 | +24.77% | ||
| 2024-04-30 | Sale | Chief Manufacturing Officer | 1,255 0.0233% | $12.71 | $15,947 | +24.77% | ||
| 2024-04-01 | Sale | director | 1,206 0.0223% | $13.07 | $15,765 | +17.09% | ||
| 2024-04-01 | Sale | CEO and President | 354 0.0065% | $13.07 | $4,627 | +17.09% |
Insider Historical Profitability
| GILEAD SCIENCES, INC. | 10 percent owner | 2209471 34.7604% | $14.72 | 2 | 0 | |
| Schornstein Alexander | 10 percent owner | 728113 11.455% | $14.72 | 9 | 0 | |
| Small Derek A | CEO and President | 669291 10.5296% | $14.72 | 3 | 0 | <0.0001% |
| ELLISON RUSSELL H | Chief Executive Officer | 58000 0.9125% | $14.72 | 6 | 0 | +59.67% |
| BARRETT DAVID JONATHAN | Chief Financial Officer | 46980 0.7391% | $14.72 | 3 | 0 | +85.85% |
Institutional Investor Ownership
| The Vanguard Group | $2.61M | 3.21 | 196,368 | -91.61% | -$28.5M | <0.0001 | |
| Millennium Management LLC | $1.66M | 2.04 | 124,922 | -91.39% | -$17.62M | <0.01 | |
| BlackRock | $1.04M | 1.27 | 77,961 | -91.78% | -$11.57M | <0.0001 | |
| Geode Capital Management | $694,371.00 | 0.85 | 52,197 | -91.47% | -$7.45M | <0.0001 | |
| Acuitas Investments, LLC | $661,436.00 | 0.81 | 49,732 | -81.28% | -$2.87M | 0.35 |